JP2013521286A5 - - Google Patents

Download PDF

Info

Publication number
JP2013521286A5
JP2013521286A5 JP2012556122A JP2012556122A JP2013521286A5 JP 2013521286 A5 JP2013521286 A5 JP 2013521286A5 JP 2012556122 A JP2012556122 A JP 2012556122A JP 2012556122 A JP2012556122 A JP 2012556122A JP 2013521286 A5 JP2013521286 A5 JP 2013521286A5
Authority
JP
Japan
Prior art keywords
hydroxy
aryl
heterocyclyl
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556122A
Other languages
English (en)
Japanese (ja)
Other versions
JP5860417B2 (ja
JP2013521286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/026414 external-priority patent/WO2011109261A1/en
Publication of JP2013521286A publication Critical patent/JP2013521286A/ja
Publication of JP2013521286A5 publication Critical patent/JP2013521286A5/ja
Application granted granted Critical
Publication of JP5860417B2 publication Critical patent/JP5860417B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012556122A 2010-03-04 2011-02-28 カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 Expired - Fee Related JP5860417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31040010P 2010-03-04 2010-03-04
US61/310,400 2010-03-04
PCT/US2011/026414 WO2011109261A1 (en) 2010-03-04 2011-02-28 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders

Publications (3)

Publication Number Publication Date
JP2013521286A JP2013521286A (ja) 2013-06-10
JP2013521286A5 true JP2013521286A5 (enExample) 2014-04-17
JP5860417B2 JP5860417B2 (ja) 2016-02-16

Family

ID=44542512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556122A Expired - Fee Related JP5860417B2 (ja) 2010-03-04 2011-02-28 カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用

Country Status (11)

Country Link
US (1) US9309199B2 (enExample)
EP (1) EP2542077A4 (enExample)
JP (1) JP5860417B2 (enExample)
KR (1) KR20130044381A (enExample)
CN (1) CN102933079B (enExample)
AU (1) AU2011223976B2 (enExample)
BR (1) BR112012021659A2 (enExample)
CA (1) CA2789474A1 (enExample)
MX (1) MX2012010188A (enExample)
RU (1) RU2563634C2 (enExample)
WO (1) WO2011109261A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
WO2013185284A1 (en) * 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
CA2886139A1 (en) * 2012-12-27 2014-07-03 F. Hoffmann-La Roche Ag Comt inhibitors
EP3077376B1 (en) 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
CR20160494A (es) * 2014-04-25 2016-12-20 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
JPWO2015178342A1 (ja) * 2014-05-20 2017-04-20 マナック株式会社 モノカップリング体の製造方法
ES2912921T3 (es) 2016-04-29 2022-05-30 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
US11339142B2 (en) * 2016-09-07 2022-05-24 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CN106946766B (zh) * 2017-05-11 2019-07-02 辽宁中医药大学 马齿苋中生物碱化合物及其提取分离方法
US11220482B2 (en) 2017-11-03 2022-01-11 Universite Amiens Picardie Jules Verne Aminopyridinemethanol compounds and their use
US11466027B2 (en) * 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
CN118632633A (zh) 2022-02-04 2024-09-10 罗塞洛公司 胶原蛋白水解物在预防和/或治疗食物渴求中的用途
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225601A (en) * 1979-09-10 1980-09-30 Sterling Drug Inc. 3-Hydroxy or hydroxymethyl-5-(4-pyridinyl)2(1H)-pyridinones, useful as cardiotonic agents and their preparation
US4361569A (en) 1981-08-26 1982-11-30 Sterling Drug Inc. 3-(Hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone and cardiotonic use thereof
US4539321A (en) * 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
GR78491B (enExample) * 1982-03-24 1984-09-27 Nat Res Dev
GB9625638D0 (en) 1996-12-10 1997-01-29 Cenes Ltd Therapeutic antioxidants for alzheimer's diease
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
GB9723078D0 (en) 1997-10-31 1998-01-07 Cerebrus Ltd Chemical compounds
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
TWI330183B (enExample) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
DE60209381T2 (de) * 2001-10-26 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
JP4453320B2 (ja) 2002-09-30 2010-04-21 萬有製薬株式会社 N−置換−2−オキソジヒドロピリジン誘導体
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
CA2554120A1 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors
US20090012177A1 (en) * 2006-03-23 2009-01-08 Rahim Shafa Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法

Similar Documents

Publication Publication Date Title
RU2012142180A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств
JP2012521428A5 (enExample)
JP2013521288A5 (enExample)
JP2012521429A5 (enExample)
RU2012142171A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
JP2016512825A5 (enExample)
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP2009523165A5 (enExample)
JP2014530900A5 (enExample)
JP2011502958A5 (enExample)
JP2013543896A5 (enExample)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2010533160A5 (enExample)
RU2010146485A (ru) Новые лиганды эстрогеновых рецепторов
JP2014508811A5 (enExample)
JP2009523760A5 (enExample)
JP2011528658A5 (enExample)
JP2014505107A5 (enExample)
JP2017505293A5 (enExample)
RU2015121043A (ru) Производные фенилэтилпиридина в качестве ингибиторов PDE-4
JP2017537954A5 (enExample)
JP2017500321A5 (enExample)
JP2017525717A5 (enExample)
JP2018535235A5 (enExample)
JP2014518212A5 (ja) 化合物及び組成物